PPARA rs1800206: What Your Genotype Means
The PPARA rs1800206 variant is a common genetic change in the PPARA gene that alters the structure of a key protein involved in fat metabolism. Research suggests this variant may influence how an individual's triglyceride levels respond to dietary intake of polyunsaturated fatty acids (PUFAs).
What each genotype means
Typical lipid and PUFA response
You carry two copies of the common C allele, coding for the conventional leucine at position 162 (Leu162Leu). Research associates this genotype with typical baseline triglyceride and total cholesterol levels as well as standard lipid responses to dietary polyunsaturated fatty acids. Observed outcomes remain variable as overall lipid metabolism is shaped by multiple genes and lifestyle factors.
Carried by approximately 85% to 90% of individuals of European descent and over 98% of individuals of East Asian ancestry.
Altered lipid response to dietary fat
You carry one copy of the less common G allele, corresponding to the Leu162Val missense substitution. Population studies show this genotype is modestly associated with differences in fasting triglyceride, LDL, and apolipoprotein concentrations, particularly in interaction with dietary polyunsaturated fatty acid (PUFA) intake. However, findings across diverse cohorts are mixed and represent modest statistical correlations rather than direct clinical diagnostic outcomes.
Carried by roughly 10% to 15% of people of European ancestry, but rare (less than 2%) in East Asian populations.
Pronounced dietary fat interaction
You carry two copies of the uncommon G allele, resulting in the homozygous Val162Val substitution. Research suggests homozygous carriers may experience more pronounced shifts in blood lipid concentrations, including fasting triglycerides, depending on the composition and level of dietary fat. Because this genotype is relatively rare in the population, clinical evidence remains limited and prospective effects can vary widely between individuals.
Carried by fewer than 1% of individuals across most global populations, including those of European descent.
What is the rs1800206 Variant?
The rs1800206 variant, often referred to as the Leu162Val polymorphism, is a single nucleotide change in the PPARA gene. This specific change results in a missense mutation where the amino acid leucine is replaced by valine at position 162 of the PPARα protein. This location is significant because it sits within the DNA-binding domain of the protein, which is essential for its function as a transcription factor. Because this change alters the protein's structure, researchers have long investigated whether it affects the efficiency with which the protein regulates other genes. In scientific literature, this variant is sometimes historically referred to as PPARA*3. It is classified as a polymorphism, meaning it is a common variation found in the general population rather than a rare disease-causing mutation.
The Role of the PPARA Gene
The PPARA gene provides instructions for making the peroxisome proliferator-activated receptor alpha (PPARα) protein. This protein acts as a sensor for fatty acids in the body, particularly in the liver, where it plays a central role in regulating lipid metabolism. When activated by fatty acids or other ligands, PPARα binds to specific regions of DNA to turn on genes involved in the breakdown of fats, a process known as fatty acid catabolism. By controlling these pathways, PPARα helps maintain healthy levels of circulating lipids, such as triglycerides and cholesterol. Because of its central role in energy balance and fat processing, variations in the PPARA gene are frequently studied for their potential impact on cardiovascular health and metabolic traits.
Research Associations and Evidence Strength
Evidence linking rs1800206 to health outcomes is considered limited and often dependent on environmental factors, such as diet. Studies have observed that the Val162 allele can influence how the body responds to dietary polyunsaturated fatty acids (PUFAs). For example, some research indicates that carriers of the Val162 allele may show different triglyceride and apolipoprotein C-III responses depending on their total PUFA intake. Additionally, there is some evidence suggesting that this variant might influence the response to lipid-lowering medications like fenofibrate, though findings have been mixed across different study populations. It is important to note that many of these associations are identified through gene-nutrient or gene-drug interactions, meaning the effect of the genotype may be masked or amplified by an individual's specific lifestyle or medical treatment.
Understanding Your Results
If you have information about your PPARA genotype, it is important to interpret it within the context of your overall health. This variant is not a diagnostic tool and does not predict a specific medical outcome. Because the associations with lipid levels are often tied to complex interactions with diet and medication, you cannot use this information to make independent health decisions. If you are concerned about your lipid profile, triglyceride levels, or how your diet might be affecting your cardiovascular health, you should discuss these results with a healthcare provider or a registered dietitian. Furthermore, if you are taking medications to manage cholesterol or triglycerides, do not alter your dosage or treatment plan based on genetic information without consulting your clinician or pharmacist.
How common is this variant?
The Val allele (G) is found in approximately 5-8% of European populations, while it is considered rare (less than 1%) in East Asian populations.
Frequently asked questions
Is the PPARA rs1800206 variant a cause of heart disease?
No, this variant is not a direct cause of heart disease. It is a common genetic polymorphism that may modulate how your body processes fats, but it does not determine your risk for cardiovascular conditions on its own.
Should I change my diet based on my PPARA genotype?
You should not make significant dietary changes based solely on this genetic variant. Any adjustments to your diet for health purposes should be discussed with a doctor or a registered dietitian who can consider your full medical history.
Does this variant affect how I respond to statins?
The research on rs1800206 primarily focuses on dietary fat interactions and responses to fibrate-class medications like fenofibrate. There is no strong evidence that this variant significantly alters the response to statins.
Where can I find more information about my specific genotype?
You can consult resources like the GWAS Catalog or PubMed to read about the latest research on PPARA. For personal health questions, always speak with a qualified healthcare professional.
Sources & further reading
Educational information only, last refreshed 10/28/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1800207?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in PPARA
Intron variant in PPARA associated with lipid substrate utilization and submaximal aerobic exercise capacity.
The Leu162Val variant in PPARA modulates lipid response and triglyceride clearance in response to dietary PUFA intake.
The PPARA Leu162Val polymorphism modulates fasting triglyceride and cholesterol responses to dietary polyunsaturated fatty acid (PUFA) intake.
Intronic regulatory polymorphism in PPARA associated with lipid metabolism and cardiovascular fitness profiles.
Influences PPARA expression and is associated with variations in cholesterol levels and response to dietary fat intake.
This SNP is associated with the capacity to improve VO2max in response to endurance training and metabolic efficiency.